Skip to content
Precision for Medicine
Contact Us
Now Available

The Institute@Precision Radiopharmaceutical Series: Five New Whitepapers

Read More
patient-recruitement-2

Patient Recruitment Strategies

Finding the right patients for your trial can be challenging, especially when affected populations are small, such as for rare disease trials. Contact Us
Precision’s holistic patient recruitment approach leverages our global reach, extensive network of disease researchers, and patient advocacy groups to assemble a strategy to match the patient to your clinical trial based on your study’s criteria. For targeted therapeutics, we use biomarker-driven screening to find the patients expected to respond to your therapeutic, moving quickly and with confidence in data quality thanks to our in-house specialty lab services.

Smart patient recruitment strategies

Our network spans the globe, just like your patients do

patient_rec_img

Building relationships with communities and specialists

Patient advocacy group relationships and social media outreach help reach into affected communities.

Meanwhile, our established relationships with key opinion leaders and clinical research sites around the globe secure access to a wide range of patient populations.

Case Study: Enrolling a global natural history study: How to find 200 rare patients

A sponsor selected Precision to manage a global natural history study in a rare, X-linked kidney disorder. The study had been recommended by the FDA because there was extremely limited published data on this rare disease—the goal was to characterize renal function and decline in patients with the disease prior to initiating a phase 2/3 clinical study. The study, to be conducted in the United States, Canada, Australia and in Europe, would follow 200+ patients for approximately 2 years.

Enrollment was by far the greatest study challenge, combining a low disease prevalence and a primary target population—young males—with life commitments such as school and work that left little time for participation in a trial that offered no therapeutic benefit for participants and would require traveling to a clinic every 3 to 6 months.

Download now

Read the latest insights on Precision’s blog

Discover expert analysis and broaden your understanding through Precision’s Insights on current research, case studies, and trends. 

Explore our blog
Read: China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches

Clinical Trials

China’s New Drug Regulatory Framework Positions the Country as a Global Hub for Innovative Medicine Launches

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=209983237513, hs_child_table_id=0, hs_updated_at=1774533604788, hs_published_at=1775839468505, description=Calvin Niu received his BD in pharmaceuticals from Lanzhou University. He has brought over 22 years of drug development and regulatory experience in pharmaceutical companies and CROs. Calvin’s regulatory expertise covers regulatory agency engagements and all types of regulatory submissions throughout product development and post market life cycles in oncology, immunology, ophthalmology, clinical nutrition, cardiovascular, gastroenterology, women’s health, CNS, rare disease, etc. , avatar=Image{width=276,height=290,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Calvin%20Niu.png',altText='Calvin Niu',fileId=209991702802}, lastname=Niu, hs_initial_published_at=1774533614867, hs_created_by_user_id=51739740, hs_created_at=1774531720533, hs_is_edited=false, hs_deleted_at=0, name=Calvin, job=Director, Regulatory Affairs, China, slug=calvin-niu, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Calvin Niu avatar

    Calvin Niu
Discover
Read: Bringing Early Phase Oncology Closer to Patients in Los Angeles Bringing Early Phase Oncology Closer to Patients in Los Angeles

Clinical Trials - Oncology

Bringing Early Phase Oncology Closer to Patients in Los Angeles

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778858, hs_child_table_id=0, hs_updated_at=1754641583843, hs_published_at=1775839468505, description=Rob Maiale is a marketing strategist and creative technologist with 17 years of experience turning complex ideas into growth. He currently leads content strategy, where he transforms insights from Precision experts into market-shaping narratives that drive the advancement of next-generation therapies.  Rob’s career spans journalism, advertising, and brand storytelling, with a through-line of making the meaningful memorable. His work blends creative strategy with emerging AI tools to help Precision stay ahead of the curve—and above the noise., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/rob.png',altText='rob',fileId=194099000843}, linkedin=https://www.linkedin.com/in/rob-maiale/, hs_name=, hs_path=, lastname=Maiale, hs_initial_published_at=1775839468505, hs_created_at=1709645745089, hs_is_edited=false, hs_deleted_at=0, name=Rob, position=Associate Director, Digital Content & Inbound Marketing, job=, slug=rob-maiale, email=, hs_updated_by_user_id=51739740}, second={}, third={}})
  • Rob Maiale avatar

    Rob Maiale
Discover
Read: Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO

Clinical Trials - Oncology

Radiopharmaceutical Clinical Trials: What Sponsors Need to Know About Selecting a CRO

|
    has not third author: true, (SizeLimitingPyMap: {main={hs_id=159488778843, hs_child_table_id=0, hs_updated_at=1774960706353, hs_published_at=1775839468505, description=Robert Bauer is an Executive Director of Operational Strategy at Precision with over 20 years of clinical trial operations experience from both the sponsor and CRO perspectives. He has led teams in the conduct of trials from Phase I through IV and has experience across a wide variety of trial designs. Bob has experience across many therapeutic areas some of which include rare diseases, oncology, depression, schizophrenia, and substance use disorders., avatar=Image{width=576,height=576,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/Headshots/Headshots%20no%20background/Robert%20Bauer%20Square.webp',altText='Robert Bauer Square',fileId=165892429961}, linkedin=https://www.linkedin.com/in/robert-bauer-a78b704b, hs_name=, hs_path=, lastname=Bauer, hs_initial_published_at=1775839468505, hs_created_at=1709645745074, hs_is_edited=false, hs_deleted_at=0, name=Robert, position=Vice President, Operational Strategy, job=, slug=robert-bauer, email=, hs_updated_by_user_id=51739740}, second={hs_id=185416008260, hs_child_table_id=0, hs_updated_at=1754641208207, hs_published_at=1775839468505, description=Sarika is a Senior Clinical Trial Manager with 14+ years of experience in clinical research, specializing in oncology, rare diseases, and cardiology. With a robust focus on Phase I-IV clinical trials, she has successfully led projects from start-up to close-out and has experience in cohort management and solid tumor studies. She is a strong advocate for cross-functional teamwork, streamlining processes, and optimizing project efficiency., avatar=Image{width=287,height=287,url='https://5014803.fs1.hubspotusercontent-na1.net/hubfs/5014803/PfM%20Website/PfMxMarkentive/authors/Sarika-David-Armogan-1-1.png',altText='Sarika-David-Armogan-1-1',fileId=194123711873}, lastname=David-Armogan, hs_initial_published_at=1737992355064, hs_created_by_user_id=26433386, hs_created_at=1737992180108, hs_is_edited=false, hs_deleted_at=0, name=Sarika, slug=sarika-david-armogan, hs_updated_by_user_id=51739740}, third={}})
  • Robert B. avatar

    Robert B.
  • Sarika D. avatar

    Sarika D.
Discover